Resources

In the evolving landscape of clinical research, the era of one-size-fits-all clinical trials is firmly behind us. Regulatory bodies and industry leaders alike recognize the necessity of diverse representation in trials to ensure that medical treatments are effective for all populations.

Multiple myeloma (MM) is a rare and complex blood cancer that affects plasma cells in the bone marrow. These malignant cells accumulate and interfere with normal blood cell production, leading to complications such as anemia, kidney dysfunction, bone lesions, and increased susceptibility to infections.

The integration of digital technology is transforming clinical research, improving the efficiency of trial design and execution. A key innovation in this space is the digital waiting room, which leverages real-world data (RWD) and artificial intelligence (AI) to enhance the critical “last mile” of a trial—when sites are activated, and patient recruitment begins. 

SCOPE 2025, held from February 3-6 in Orlando, Florida, brought together over 4,500 leaders in clinical operations and research to discuss the latest advancements in clinical trial innovation, planning, management, and operations

Partnership taps real-world data to accelerate clinical trials, research, and drug development in Japan.   

In a rapidly evolving healthcare landscape, artificial intelligence (AI) is emerging as a transformative force in drug development and clinical research. With the average cost of bringing a new drug to market soaring to $1.3 billion and a low probability of success, the stakes for innovation have never been higher.

HES is a group of rare disorders characterized by persistent hypereosinophilia in blood and/or tissues, causing organ damage/dysfunction; real-world treatment patterns of patients with I-HES or L-HES remain unknown.

Adverse Drug Events (ADEs) or Adverse Drug Reactions (ADRs) continue to be a concern both in new and existing medicines. According to Medication Safety Data published by the U.S. Centers for Disease Control and Prevention (CDC), ADEs cause more than 1.5 million emergency department (ED) visits each year and nearly 500,000 patients are hospitalized after these ED visits

In the dynamic world of healthcare, real-world data (RWD) and the real-world evidence (RWE) derived from it stand as a crucial pillar for informed insights and actions.

Clinical trials are the bedrock of medical advancement, but they often grapple with a persistent challenge: ensuring diverse and representative participation. This issue isn’t just a matter of ethics—it’s crucial for delivering effective, equitable healthcare solutions.   

After 11 Years, Gadi Lachman to Conclude Operating Role, Remain on TriNetX’s Board

In an era defined by rapid advancements in technology and science, healthcare research and clinical trials are undergoing a transformative shift. At the heart of this revolution is data—vast, diverse, and ever-growing—and the collaborative efforts of stakeholders across the healthcare ecosystem.